Table 2.
Clinicopathological associations with intra-epithelial tumour-infiltrating lymphocytes
| Intra-epithelial lymphocytes | P | ||
|---|---|---|---|
| Yes (n = 130) | No (n = 242) | ||
| Gender, n% | |||
| Male | 53, 40.8% | 136, 56.2% | 0.0045 |
| Female | 77, 59.2% | 106, 43.8% | |
| Age, mean ± SD | 67.4 ± 13.7 | 64.7 ± 12.4 | 0.0470 |
| Race, n% | |||
| Caucasian | 109, 83.9% | 205, 84.7% | 0.4061 |
| African American | 16, 12.3% | 33, 13.6% | |
| Other1 | 5, 3.9% | 4, 1.7% | |
| History of prior malignancy, n% | |||
| Yes | 18, 13.9% | 36, 14.9% | 0.7880 |
| No | 112, 86.2% | 206, 85.1% | |
| Known Lynch syndrome, n% | |||
| Yes | 3, 2.3% | 4, 1.7% | 0.6990 |
| No | 127, 97.7% | 238, 98.4% | |
| CEA level at resection, n, mean ± SD | 93, 5.6 ± 9.9 | 182, 7.5 ± 25.1 | 0.8593 |
| Adjuvant chemotherapy, n% | n =129 | n = 242 | |
| Yes | 33, 25.6% | 72, 29.8% | 0.3957 |
| No | 96, 74.4% | 170, 70.3% | |
| Location, n% | |||
| Right | 88, 67.7% | 139, 57.4% | 0.0532 |
| Left | 42, 32.3% | 103, 42.6% | |
| Tumour buds, n% | |||
| Low | 115, 88.6% | 187, 77.3% | 0.0247 |
| Intermediate | 8, 6.2% | 23, 9.5% | |
| High | 7, 5.4% | 32, 13.2% | |
| Desmoplastic reaction, n% | |||
| Immature/myxoid | 11, 8.5% | 56, 23.1% | 0.0004 |
| Intermediate | 47, 36.2% | 93, 38.4% | |
| Mature | 72, 55.4% | 93, 38.4% | |
| Tumour grade, n% | |||
| Well/moderately differentiated | 90, 69.2% | 204, 84.3% | 0.0015 |
| Poorly differentiated | 31, 23.9% | 25, 10.3% | |
| Mucinous carcinoma | 9, 6.9% | 13, 5.4% | |
| Lymphovascular invasion, n% | |||
| Yes | 40, 30.8% | 98, 40.5% | 0.0641 |
| No | 90, 69.2% | 144, 59.5% | |
| Perineural invasion, n% | |||
| Yes | 13, 10.0% | 44, 18.2% | 0.0367 |
| No | 117, 90.0% | 198, 81.8% | |
| Tumour deposits, n% | |||
| Yes | 13, 10.0% | 30, 12.4% | 0.4906 |
| No | 117, 90.0% | 212, 87.6% | |
| Number of tumour deposits, mean ± SD | 0.6 ± 3.2 | 0.3 ± 1.0 | 0.5392 |
| Number of involved lymph nodes, mean ± SD | 1.3 ± 2.8 | 1.3 ± 2.7 | 0.5139 |
| Number of lymph nodes evaluated, mean ± SD | 20.4 ± 8.9 | 20.0 ± 7.5 | 0.9093 |
| MMR expression, n% | N = 115 | N = 209 | |
| Deficient | 37, 32.2% | 30, 14.4% | 0.0002 |
| Proficient | 78, 67.8% | 179, 85.7% | |
| pT stage, n% | |||
| pT1 | 8, 6.2% | 18, 7.4% | 0.9127 |
| pT2 | 28, 21.5% | 46, 19.0% | |
| pT3 | 78, 60.0% | 146, 60.3% | |
| pT4 | 16, 12.3% | 32, 13.2% | |
| pN stage, n% | |||
| pN0 | 86, 66.2% | 147, 60.7% | 0.5362 |
| pN1 | 27, 20.8% | 62, 25.6% | |
| pN2 | 17, 13.1% | 33, 13.6% | |
| pTNM prognostic group, n% | |||
| I | 29, 22.3% | 54, 22.3% | 0.5279 |
| II | 57, 43.8% | 93, 38.4% | |
| III | 44, 33.8% | 95, 39.3% | |
SD, standard deviation; CEA, carcinoembryonic antigen; MMR, mismatch repair protein; pT, pathological T category; pTNM, pathological tumour–node–metastasis.
a
Asian or Hispanic percentages might not total 100% due to rounding.
Bold indicates statistical significance.